US 12,186,401 B2
Amide-based proteolysis modulators of B-rapidly accelerated fibrosarcoma (BRAF) and associated uses
Frank Sicheri, Toronto (CA); Ganna Posternak, Toronto (CA); and Gennady Poda, Toronto (CA)
Assigned to Ontario Institute for Cancer Research (OICR) and Sinai Health System, Toronto (CA)
Appl. No. 17/310,837
Filed by Ontario Institute for Cancer Research (OICR), Toronto (CA); and Sinai Health System, Toronto (CA)
PCT Filed Mar. 2, 2020, PCT No. PCT/CA2020/050280
§ 371(c)(1), (2) Date Aug. 26, 2021,
PCT Pub. No. WO2020/176983, PCT Pub. Date Sep. 10, 2020.
Claims priority of provisional application 62/812,567, filed on Mar. 1, 2019.
Prior Publication US 2022/0125936 A1, Apr. 28, 2022
Int. Cl. A61K 47/55 (2017.01); A61K 47/54 (2017.01); A61P 35/00 (2006.01); C07D 471/04 (2006.01)
CPC A61K 47/55 (2017.08) [A61K 47/54 (2017.08); A61K 47/545 (2017.08); A61P 35/00 (2018.01)] 20 Claims
 
1. A compound of Formula I or a pharmaceutically acceptable salt and/or solvate thereof:

OG Complex Work Unit Chemistry
wherein

OG Complex Work Unit Chemistry
is a linker group, and

OG Complex Work Unit Chemistry
represents a point of covalent attachment.